Resolve Therapeutics is pioneering safe, targeted therapies for underserved patients with autoimmune diseases. Our lead program, RSLV-132, is designed to prevent chronic, systemic inflammation that may cause organ damage and the symptoms associated with autoimmune diseases. RSLV-132 is a first-in-class RNase-Fc fusion protein being developed to treat patients with lupus and Sjögren’s syndrome. We are conducting a Phase 2a study of RSLV-132 in lupus and will be initiating a Phase 3 study in Sjögren’s syndrome in 2020.
OUR COMPANY
Management Team
Founder and Chief Executive Officer
Jim Posada, Ph.D., MBA, is founder and Chief Executive Officer…
read more
James Posada, PH.D., MBA
Founder and Chief Executive Officer
Jim Posada, Ph.D., MBA, is founder and Chief Executive Officer of Resolve Therapeutics. Previously, Jim was Chief Business Officer of GlycoFi, where he designed the business strategy and executed partnerships, including the 2006 sale of the company to Merck. Jim is a scientist who has made important contributions to the field of signal transduction, including the identification and cloning of the first full length MAP kinase ERK2, and identifying the upstream activating kinase MEK. Following his postdoctoral training with Jonathan Cooper, he was a faculty member at the University of Vermont School of Medicine where he built an NIH-funded basic research group. From academics, Jim pivoted into drug discovery, joining Eli Lilly where he led multiple research groups as a member of the biotherapeutics management team.
Close
Chairman of the Board of Managers
Dr. Peter Kiener is an experienced veteran in pharmaceutical…
read more
Peter Kiener, PH.D.
Chairman of the Board of Managers
Dr. Peter Kiener is an experienced veteran in pharmaceutical development. He previously served as Chief Scientific Officer of Ambrx Inc., a clinical stage biopharmaceutical company focused on the development of antibody-drug conjugates. Prior, he was President and co-founder of Zyngenia Inc., an early stage biopharmaceutical company. He held leadership roles at MedImmune, including Executive Vice President and Global Head of Biologics Research and Development, Senior Vice President and Head of Global Research, and Vice President of Research. Dr. Kiener began his career at the University of North Texas/Texas College of Osteopathic Medicine, where he was an Assistant Professor, and the University of Massachusetts at Amherst, where he was a Research Associate. Dr. Kiener has served on the scientific advisory boards of KAI Pharmaceuticals Inc., Genocea Biosciences Inc., NKT Therapeutics Inc. and VLST Corporation. He has published more than 120 papers in peer-reviewed journals, and is an inventor on more than 40 patents and patent applications. Dr. Kiener earned a Bachelor’s degree in chemistry from the University of Lancaster and a Doctorate of Philosophy in biochemistry from the University of Oxford.
Close
Medical
Dr. Dan Burge has provided clinical and strategic consulting services to…
read more
Daniel Burge, M.D.
Medical
Dr. Dan Burge has provided clinical and strategic consulting services to the biopharma and pharmaceutical industry since founding Burge Consulting in 2008. Prior, Dr. Burge was the Chief Medical Officer of Trubion Pharmaceuticals, where he managed the development of two novel oncology biotherapeutic molecules. He began his career at Immunex Corporation, where he was the inflammation area head. During his tenure, he was instrumental in the development of the first anti-TNF therapy, Enbrel. Dr. Burge is a rheumatologist, and was in private practice prior to joining Immunex
Close
Regulatory
Jeff Fellows is a seasoned pharmaceutical industry professional …
read more
Jeff Fellows
Regulatory
Mr. Fellows is a seasoned pharmaceutical industry professional with over 30 years of drug development experience leading regulatory development efforts. During his career, he has worked with early stage development companies and a large multinational biopharmaceutical enterprise developing products across numerous therapeutic areas. Prior to his current role, Mr. Fellows held senior positions in Regulatory Affairs at Amgen and Cell Therapeutics, Inc. His experience in both North America and Europe includes extensive clinical trial application filings, marketing applications, and health authority interactions, leading to the conduct of global licensing trials and approvals. He has a B.S. in Microbiology from Oregon State University.
Close
Regulatory Lead - Chemistry, Manufacturing and Controls
Dr. Raj Dua oversees regulatory functions, including the process…
read more
Raj Dua, PH.D.
Regulatory Lead – Chemistry,
Manufacturing and Controls
Dr. Raj Dua oversees regulatory functions, including the process development, manufacturing, and drug supply for Resolve Therapeutics. Dr. Dua has over 20 years of experience in product development, bringing biologics and pharmaceutical candidates from discovery to commercialization, and his career includes the development of cell based therapies, monoclonal antibodies, and fusion proteins. Most recently, he was Vice President, Pharmaceutical Operations at Alder Bio-Pharmaceuticals, overseeing the development, manufacturing, and supply chain management for their monoclonal antibody products. Prior, he was Senior Director of Product Development at Trubion Pharmaceuticals and Director of Process and Assay Development at Xcyte Therapies. Dr. Dua received his Ph.D. at the University of Georgia and his MBA at the University of Washington. He has published several scientific articles and is the inventor on numerous patents.
Close
Clinical Advisory Board
The Feinstein Institute
Head Rheumatology, Univ. Washington
Northwell Health
Oklahoma Res. Foundation
Johns Hopkins
Cedars-Sinai
University of Pennsylvania
University of California San Francisco